relative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors (NCBI Entrez Gene 3845) do not benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab.
cific. Although colorectal tumors have both codon 12 and codon 13 mutations (79% and 17.6%, respectively), KRASmutated pancreatic tumors (75%-95%) almost invariably carry codon 12 mutations, and in non-small cell lung cancer, more than 90% of KRAS mutations are located in codon 12. 5 Second, anecdotal reports indicate that a minority of patients (Ͻ10%) with KRAS-mutated tumors can respond to anti-EGFR therapy [6] [7] [8] [9] and that about 15% have longterm disease stabilization. 10 In these patients' tumors, codon 13 mutations were overrepresented compared with the overall KRAS-mutated tumor population. Finally, KRAS codon 13 mutations exhibit weaker in vitro transforming activity than codon 12 mutations. 11 Based on these observations, we hypothesized that KRAS codon 13 mutations may be associated with a better outcome after cetuximab treatment than observed with other KRAS mutations. Because the glycine (G)-to-aspartate (D) transition mutation is the most frequent codon 13 mutation in colorectal cancer, 5 we studied the association of this p.G13D mutation with outcome after cetuximab treatment in a pooled data set of 579 patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab with or without chemotherapy.
METHODS

Description of Data Sets
All patients included had chemotherapyrefractory metastatic colorectal cancer. The National Cancer Institute of Canada Clinical Trials Group/Australasian Gastrointestinal Trials Group (NCIC CTG/ AGITG) data set is from the CO.17 randomized phase 3 trial of cetuximab plus best supportive care vs best supportive care alone. 12 KRAS mutation analysis was performed by direct sequencing as described previously. 13 All centers participating in the NCIC CTG CO.17 trial received approval from their local research ethics body for participation in the trial, including for collection of tissue for correlative biomarker analyses, and all NCIC CTG/ AGITG patients provided written informed consent for the original clinical trial. The Leuven data set comprises patients from 4 clinical trials (EVEREST, BOND, SALVAGE, and BABEL). [14] [15] [16] KRAS mutation analysis was performed by allelic discrimination assay as described previously. 10 The Italian data set comprises patients treated at the Ospedale Niguarda Ca'Granda in Milan, Italy, and the Ospedale San Giovanni in Bellinzona, Cantone Ticino, Switzerland. Patients were included in 3 clinical trials (BOND, MABEL, and EMR202600) 15, 17, 18 or were considered suitable to receive a subsequent line of treatment off study (after becoming refractory to the standard chemotherapy lines). KRAS mutation analysis was performed by direct sequencing as described previously. [6] [7] [8] All patients in the Leuven and Italian data sets provided written informed consenttotheoriginalclinicaltrialandtomolecular analyses. The Italian data set had a significantly higher percentage of patients with KRAS wild-type tumors than the other data sets (PϽ.001) because of the early introduction of KRAS testing in Italy, leading to exclusion of patients with KRAS-mutated tumors from treatment withcetuximab.Adetailedbreakdownaccounting for the number of participants witheachKRASmutationtypeandpatient characteristics is presented for each data set in the eTable (available online at http: //www.jama.com).
End Points
The main efficacy end point was overall survival, defined as time from randomizationintheNCICCTG/AGITGdataset, fromstartofcetuximabintheLeuvendata set, and from start of cetuximab or date of randomization in the Italian data set to death due to any cause or to last known date alive. Secondary efficacy end points were response rate and progression-free survival. Tumor response was evaluated byradiologicimagingevery8weeksinthe NCIC CTG/AGITG data set and every 6 weeks until week 24, 30, or 36 and from thenonevery12weeksintheLeuvendata set and for trial patients in the Italian data set. Response Evaluation Criteria in Solid Tumors were used to classify tumor response in all data sets. Progression-free survival was defined as the time from randomization or start of cetuximab to diseaseprogressionordeathduetoanycause. If a patient had not progressed or died at the time of data cutoff, progression-free survival was censored on the date of last disease assessment (NCIC CTG/AGITG data set) or last radiologic assessment (Leuven and Italian data sets).
Statistical Analysis
Differences in response rates by KRAS status (p.G13D mutant, other KRAS mutant, or KRAS wild-type) were evaluated pairwise using the Fisher exact test. Median overallandprogression-freesurvivalwere estimated by the Kaplan-Meier method and compared between groups using the log-rank test. Hazard ratios (HRs) between groups were estimated from Cox regression models including the following potential prognostic factors: age (Ͻ65 vs Ն65 years), sex (male vs female), performance status (Eastern Cooperative Oncology Group performance score, 0-1 vs 2), whether all 3 chemotherapy drugs (fluoropyrimidine [fluorouracil or capecitabine], irinotecan, and oxaliplatin)werepreviouslyreceived(yes vs no), site of primary malignancy (rectum only vs colon), data set (NCIC CTG/ AGITG vs Leuven vs Italian), and an interaction term between KRAS status and treatment group as indicated.
For the predictive analysis (association between mutation status and outcome after cetuximab treatment), an additional analysis using the CO.17 database only was also undertaken. This was performed as a sensitivity analysis (avoiding the potential bias associated with cross-trial comparisons) rather than as the primary analysis because of the smaller number of patients (n=195). All P values were 2-sided and statistical significance was assumed for PϽ.05. No adjustments were made for multiple comparisons. Analyses were carried out using SAS software, version 9 (SAS Institute Inc, Cary, North Carolina).
Measurement of Cetuximab Sensitivity in Isogenic Cell Lines
Details about the generation of KRASmutated isogenic cells, in vitro and in vivo treatment with cetuximab, proliferation assays, and biochemical profiling of signaling pathways are provided in the eAppendix.
RESULTS
Study Population
Baseline patient characteristics in the 3 data sets by KRAS mutation status demonstrated no significant differences (TABLE 1). The mutation frequencies (40% KRAS-mutated, of which 14.5% were p.G13D-mutated) and distribution in this pooled data set (eTable) are similar to those reported for randomized trial populations (between 36% and 43% KRAS-mutated, of which 15.7% were p.G13D-mutated). [19] [20] [21] [22] The objective response rate in unselected patients was 10.2% in the monotherapy group and 22.2% in the cetuximab plus chemotherapy group. The median overall and progression-free survival were, respectively, 7. because no patient responded under best supportive care.
Association of p.G13D Mutation With Outcome in Patients Receiving Cetuximab
Among patients who received any cetuximab-based treatment (cetuximab monotherapy or cetuximab plus chemotherapy) (n = 571), overall and progression-free survival were significantly longer in patients with p. with p.G13D-mutated and KRAS wildtype tumors in either of these 2 subgroups (P=.41 and P Ͼ.99 for overall survival and P=.29 and P = .31 for progression-free survival in the cetuximab monotherapy and cetuximab plus chemotherapy groups, respectively) ( We performed a test for interaction between any vs no cetuximab treatment and p.G13D vs other KRAS mutations. The adjusted P value for the interaction was P=.003 (HR, 0.30; 95% CI, 0.14-0.67) for overall survival and P =.05 (HR, 0.47; 95% CI, 0.22-1.00) for progression-free survival. There was no interaction between p.G13D mutation vs wild-type KRAS status and overall survival benefit from cetuximabbased treatment (any vs none) (HR, 0.49; 95% CI, 0.23-1.04; P=.06).
In univariate analysis, patients with p.G13D-mutated tumors had a significantly longer overall survival compared with patients receiving best supportive care (any cetuximab: HR, 0.24; 95% CI, 0.11-0.50; P Ͻ .001; cetuximab monotherapy: HR, 0.34; 95% CI, 0.13-0.87; P=.02). Similarly, progression-free survival was superior in p.G13D patients receiving any cetuximab (HR, 0.39; 95% CI, 0.19-0.78; P=.006) and cetuximab monotherapy (HR, 0.38; 95% CI, 0.15-0.98; P=.04) compared with patients receiving best supportive care alone. Although the differences were no longer statistically significant in multivariate analysis, the significant P value for interaction confirms that in this data set, the p.G13D mutation was associated with significantly greater overall survival benefit than tumors expressing other KRAS mutations (Figure 2 and FIGURE 3 ).
For patients with other KRASmutated tumors, progression-free survival was significantly longer when receiving cetuximab with chemotherapy than when receiving best supportive care alone (median, 2.8 [95% CI, 2.5-3.7] months vs 1.8 [95% CI, 1.7-1.9] months; adjusted HR, 0.53; 95% CI, 0.36-0.79; P = .002) but not when re- 
KRAS wild-type
The no cetuximab group for all patients from the pooled data set is the best supportive care group from the CO.17 trial. .
.003
Comparisons include any cetuximab therapy (with or without chemotherapy) vs no cetuximab, cetuximab monotherapy vs no cetuximab, and a sensitivity analysis including only those randomized from the CO.17 trial (cetuximab monotherapy vs no cetuximab). P values for interaction (adjusted for predefined prognostic factors) indicate capacity of biomarker to differentiate outcomes between KRAS mutation status subgroups. CI indicates confidence interval; NA, not enough data to estimate. (Figure 2) . A separate analysis of the CO.17 trial (n=195), containing the only randomized patients (cetuximab plus best supportive care vs best supportive care alone) in the pooled data set, was performed as a sensitivity analysis to avoid the potential bias associated with crosstrial comparisons and to allow the purest assessment of the impact of KRAS mutations on the effect of cetuximab.
Within the p.G13D mutation subset (n=13), the adjusted HR for overall survival for cetuximab therapy compared with best supportive care alone was in the same direction as in the cross-trial comparison, although the P value was not significant (adjusted HR, 0.61; 95% CI, 0.17-2.19; P=.45). There was no benefit for cetuximab therapy in the other KRAS mutations subset (adjusted HR, 0.99; 95% CI, 0.67-1.44; P = .94). There was a significant interaction between p.G13D mutation status (p.G13D vs other KRAS mutations) and overall survival benefit from therapy (cetuximab vs best supportive care) in the univariate analysis (HR, 0.33; 95% CI, 0.11-1.00; P=.05), which was not significant in the multivariate analysis (adjusted HR, 0.43; 95% CI, 0.14-1.34; P =.15) (FIGURE 4).
In Vitro and In Vivo Effects of p.G13D Mutation on Cetuximab Sensitivity
We introduced p.G12V and p.G13D alleles in the genome of human colorectal SW48 cells by targeted homologous recombination (eAppendix). 23 While the proliferation of p.G12V-mutated SW48 cells was unaffected by cetuximab, the isogenic p.G13D-mutated cells displayed a drug response similar to their wild-type counterpart (eFigure 1, A). Importantly, the proliferative capabilities of parental and KRAS-mutated cells were undistinguishable (eFigure 1, B). Cetuximab administration prominently inhibited the growth of tumors formed by wild-type or KRAS p.G13D mutant cells grown as xenografts in immunocompromised mice (eFigure 1, C). In contrast, the growth of tumors formed by the KRAS p.G12V cells was not significantly affected by cetuximab treatment (eFigure 1, C). We then measured the level of activation (phosphorylation status) of EGFR and its downstream effectors (mitogen-activated protein kinase/ extracellular signal-regulated kinase and v-akt murine thymoma viral oncogene homolog) in KRAS wild-type and mutant SW48 cells. In the presence of cetuximab, the p.G12V-mutated cells seemingly could still activate the extracellular signal-regulated kinase pathway but the p.G13D-mutated cells could not (eFigure 2). Of note, the levels of activated KRAS (guanosine-5Ј-triphosphate-bound) were similar in p.G12V-and p.G13D-mutated cells (eFigure 3). Overall, these results indicate that the KRAS p.G12V and p.G13D mutations differently affect response to cetuximab in preclinical models.
COMMENT
In a large, retrospective pooled exploratory analysis of patients with chemotherapy-refractory colorectal cancer, we show for the first time that there is a positive association between KRAS p.G13D mutations and cetuximab treatment in regard to better overall and progression-free survival. The improved survival observed in patients with p.G13D-mutated tumors in the cetuximab monotherapy group suggests that p.G13D-mutated tumors may be sensitive to cetuximab and precludes a chemotherapy-driven effect. Patients with p.G13D-mutated tumors treated with combination regimens also have significantly better overall survival than do those with other KRAS-mutated tumors, which mirrors the observation in monotherapytreated patients, suggesting cetuximabdependent effects, although it cannot be excluded that chemotherapy is a confounding factor in patients treated with cetuximab plus chemotherapy.
In the monotherapy group, the difference in overall and progressionfree survival between patients with p.G13D-mutated tumors and those with other KRAS-mutated tumors was not statistically significant. However, the magnitude of the effect was comparable and the direction was the same as in the patients treated with cetuximab plus chemotherapy.
Because this is a pooled analysis, to reduce the risk of biases implicit in this kind of study, we adjusted for type of previous treatment (whether all 3 chemotherapy drugs [fluoropyrimidine, irinotecan, and oxaliplatin] were previously received) and data set in the multivariate analyses. However, in the absence of randomization, there may be inadequate controlling for unknown confounders. For the predictive analysis and the estimation of treatment effect of cetuximab over no cetuximab, the comparator group for all patients from the pooled data set was the best supportive care group from the CO.17 trial. The sensitivity analysis from the CO.17 trial provided an unbiased estimate that was consistent with the finding of the pooled analysis, although it was not statistically significant.
To study the association of the p.G13D mutation with outcome in metastatic colorectal cancer, we compared overall and progression-free survival between the different KRAS mutation groups in the 195 patients in the CO.17 trial randomized to best supportive care alone. In this subset, the 13 patients with p.G13D-mutated tumors had a worse overall survival than those with KRAS wild-type tumors and those with tumors bearing other KRAS mutations, in univariate but not in multivariate analysis. Of particular relevance, patients with p.G13D-mutated tumors in our series also seemed to benefit more from cetuximab treatment than those with KRAS wild-type tumors, suggesting that the poor prognosis of a p.G13D mutation is mitigated by cetuximab treatment. Given the relatively small number of patients with p.G13D-mutated tumors, caution in drawing conclusions is warranted. Comparing overall survival between patients with p.G13D-mutated vs other KRAS-mutated and KRAS wildtype colorectal cancers in the control groups of randomized trials will contribute to determining whether this is a true association.
Although p.G13D-mutated tumors do not behave like other KRAS-mutated tumors, they appear to behave somewhat differently than KRAS wild-type tumors. Our results indicate that patients with p.G13D-mutated tumors respond to cetuximab therapy, albeit with a lower response rate than those with KRAS wildtype tumors.
The prolonged progression-free and overall survival of patients with p.G13D-mutated tumors in comparison with those with other KRASmutated tumors may not be due to a real reduction in tumor burden but to a delay in progression. A possible explanation of this clinical observation is that p.G13D mutant tumors do not undergo apoptosis (cytotoxic effect) on EGFR inhibition, but proliferation is inhibited (cytostatic effect).
When assessing the effect of cetuximab treatment on cellular proliferation in SW48 isogenic clones carrying p.G12V or p.G13D mutations, we found that while p.G12V-mutated cells were insensitive to cetuximab, p.G13-mutated cells were nearly as responsive to cetuximab as wild-type cells. These results provide a cell-based molecular explanation to our clinical observation that patients with p.G13D-mutated tumors benefit from cetuximab treatment, while those with other KRAS-mutated tumors do not.
Our study is limited because it is a retrospective observational study that relies largely on nonrandomized or cross-trial comparisons for discussion of possible treatment effects. It can therefore only suggest an association between p.G13D mutation status and survival benefit after cetuximab-based treatment. The results from the patient sample analyses are supported by isogenic cellular models, wherein the different effects of the G12 and G13 KRAS alleles on response to cetuximab are evident.
In conclusion, our study retrospectively observed an association be-tween the presence of a p.G13D mutat i o n a n d s u r v i v a l b e n e f i t i n chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Prospective randomized trials are needed before conclusions about potential beneficial effects of cetuximab in p.G13D-mutated chemotherapyrefractory metastatic colorectal cancer should be inferred.
